위암환자에서 예후인자로서 EGFR,p21(ras oncogene product) 및 p53의 연구

Abstract

There are several evidences that cancer arise as the result of multiple alterations of gene. and many attempts were made recently to understand the true role of oncogene, growth factor and its receptor, and suppressor gene as a prognostic indicator. To determine whether alterations in EGFR, ras oncogene product and p53 are associated with prognosis in gastric carcinoma, the analysis was performed on paraffin embedded tissues of 119 primary gastric carcinomas by an immunohistochemical assay using LSAB(labelled streptavidin biotin) method. EGFR was positive in 53 cases(44.5%), ras oncogene product in 21 (17.6%), and p53 in 39(32.8%). The 5-year survival rate was 57.8% in EGFR positive and 71.3% in EGFR negative, especially of the patients with serosal invasion, 44.2% in EGFR positive and 69.6% in EGFR negative(p<0.05). Ras oncogene product positive and negative had 5 years survival rate of 47.9% and 60.0% in each, and in stage II, the survival difference was more distint. The 5 year survival rate in p53 positive and p53 negative were 56.7% and 68.9% respectively(p>0.05). In patients with stage II or without serosal invasion, there was slightly survival difference between p53 positive and p53 negative. So we conclud that EGFR and ras oncogene expression are significantly associated with worse prognosis in gastric carcinomas, especially, in case of serosal invasion or stage III. Although there was no significant difference in survival rate according to p53, we suggested that p53 may be the prognostic indicator in patients with stage II or no serosal invasion.